Alain Schreiber, M.D., Partner

Dr. Schreiber joined ProQuest as a General Partner in 2000. His extensive industry experience provides a commercially-focused operational discipline and a depth of drug development expertise. Prior to joining ProQuest, Dr. Schreiber served as President, Director, and CEO of Vical. Previously, at Rhône-Poulenc Rorer (now Sanofi), Dr. Schreiber served in several roles, including Senior Vice President of Research. Prior to his tenure at Rhône-Poulenc Rorer, Dr. Schreiber was Department Head of Biochemistry at Syntex (now Roche Bioscience). He has previously served on the Board of Directors of ActivX Biosciences, Aires Pharmaceuticals, BioRexis Pharmaceutical Corp., Cabrellis Pharmaceuticals, Cadence Pharmaceuticals, Concentric Medical, Conforma Therapeutics, Excaliard Pharmaceuticals, Gemin X, LEAD Therapeutics, Optimer Pharmaceuticals and Somalogic. Currently, Dr. Schreiber serves on the Board of Directors of Eagle Pharmaceuticals, Immune Design Corporation, Revision Optics, Telormedix and Tragara Pharmaceuticals. Dr. Schreiber received a B.S. in chemistry, summa cum laude, and an M.D., summa cum laude, from the Free University in Brussels, Belgium. Subsequently, he was a postdoctoral fellow at the Weizmann Institute of Science in Israel.